Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kaletra and Viread in Antiretroviral Naïve Patients

2. december 2020 opdateret af: Johnny Stephens, Oklahoma State University Center for Health Sciences

A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra and Viread in Antiretroviral Naïve Patients.

Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to <50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study is a phase IV prospective, open-label, controlled treatment protocol consisting of once daily Kaletra dosed at 800mg lopinavir with 200mg ritonavir in four combination tablets plus Viread dosed as 300 mg tenofovir DF. This will be a single site, multi-investigator, study for 48 weeks. Consecutive eligible patients will be enrolled into the study to reach the enrollment goal of 30 patients. Eligible patients will be identified and screened during routine initial or follow-up visits at the Internal Medicine Specialty Services Clinic. This clinic serves as the HIV/AIDS specialty care clinic and is a subdivision of the Department of Internal Medicine, Oklahoma State University Center for Health Sciences College of Osteopathic Medicine. The study site currently serves >700 persons living with HIV in northeast Oklahoma with four to five antiretroviral naïve patients seen each week.

Patients meeting all inclusion criteria will receive routine standard of care for our program as prescribed by the DHHS guidelines. Patients will have a Complete Blood Count (CBC), Complete Metabolic Profile (CMP), fasting lipid profile, CD4 count, HIV-1 RNA level, and other prescribed or indicated laboratory preformed at baseline and throughout the study as described in the Visits and Evaluations section of this protocol. All of the aforementioned laboratory tests will be performed at the Diagnostic Laboratories of Oklahoma, a division of Quest Diagnostics. Any antiretroviral resistance testing will be performed at Virologic Labs, Inc. Adherence will be assessed at discontinuation of the study and when indicated for evaluation of virologic failure by Memory Electronic Monitoring Systems caps and pharmacy refill data. Patients will be monitored at each study visit for tolerability and adverse events. Patients who develop a study related Grade 1 or 2 Adverse Events (Aes) may continue the study. Those who develop Grade 3 or 4 AEs will have study medications discontinued. Patients with asymptomatic elevations of triglyceride or Low Density Lipoprotein (LDL) cholesterol levels may be treated with appropriate lipid lowering therapy at the investigators discretion.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

6

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74127
        • OSU Internal Medicine Specialty Clinic

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female patients >18 years of age with documented HIV-1 infection
  2. Naïve to antiretroviral therapy
  3. Able and willing to provide written informed consent
  4. No CD4 restriction
  5. HIV-1 RNA levels >5000 c/mL

  6. Female patients must meet these additional criteria

    1. Non-childbearing potential
    2. Negative serum pregnancy test at screen
    3. Willingness to abstain from sexual intercourse or use double barrier contraception

Exclusion Criteria:

  1. Presence of any of the following:

    1. Aminotransferases >3xULN
    2. Hemoglobin concentration <8.0g/dl
    3. Absolute neutrophil count <800 cells/cubic mm
    4. Platelet count <50,000 cells/cubic mm
    5. Acute illness, or an acute illness ≤7 days
    6. Presence of Opportunistic Infection, or an OI within 30 days of screening
    7. Acute or chronic active Hepatitis B
    8. Hepatitis C
    9. Creatinine Clearance <50 mL/min
  2. Pregnant or breast-feeding women
  3. Presence of any illness, physical or behavioral conditions (i.e., substance abuse, excluding cannabis) that will impair the patient's ability participate
  4. Patient who, in the opinion of the investigator, will be unlikely to complete the study protocol and adhere to the study drug regimens
  5. Concurrent use of medications that may potentially interact with study medications including: astemizole, terfenadine, rifampin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, St. John's wort, lovastatin, simvastatin, pimozide, midazolam, triazolam, adefovir, cidofovir, acyclovir, ganciclovir, and valganciclovir.
  6. Patient suffers from a serious medical condition that may in the opinion of the investigator compromise his or her safety.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Once daily
Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.
Medicin: Once daily
Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
Andre navne:
  • Viread
  • Kaletra

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To Assess the Efficacy of Once Daily Antiretroviral Therapy With Viread 300mg and Kaletra 800mg/200mg in Suppressing HIV RNA Levels to <50 Copies/ml in Antiretroviral naïve Patients.
Tidsramme: 4, 8, 12, 16, 24, 32, 40, and 48 weeks
To assess the efficacy of once daily antiretroviral therapy with Viread 300mg and Kaletra 800mg/200mg in suppressing HIV RNA levels to <50 copies/ml in antiretroviral naïve patients. This will be done by the proportion of patients with plasma HIV-1 RNA levels M 50 copies/ml at the end of 48 weeks of therapy.
4, 8, 12, 16, 24, 32, 40, and 48 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Patients With <400copies/ml
Tidsramme: 4,8, and 12 weeks
Proportion of patients with <400copies/ml will be done by determining plasma HIV-1 RNA levels
4,8, and 12 weeks
Review Virologic Response to Assess Rate of Viral Decline.
Tidsramme: weeks 4, 8, 12, 16, and 24
Review virologic response to assess rate of viral decline through CD4 count at baseline and throughout the study.
weeks 4, 8, 12, 16, and 24
Proportion of Patients With <50 Copies/ml HIV-1 RNA
Tidsramme: at weeks 4, 8, 12, 16, 24, 32, 40, and 48
Proportion of patients with <50 copies/ml HIV-1 RNA through evaluation of patients Plasma HIV-1 RNA levels
at weeks 4, 8, 12, 16, 24, 32, 40, and 48
Change From Baseline CD4 Counts
Tidsramme: at weeks 4, 8, 12, 16, 24, 32, 40, and 48
CD4 count done at baseline and throughout the study.
at weeks 4, 8, 12, 16, 24, 32, 40, and 48
Time to Virologic Failure.
Tidsramme: Week 48
Virologic failure is defined by any of the following: 1) <1 log10 decline in HIV RNA by week 8 of therapy; 2) failure to achieve <50 c/mL by week 24; 3) HIV RNA> 500 c/ML on two consecutive occasions (less than 30 days apart), with no evidence of suppression after adherence counseling. When HIV RNA levels are obtained >500 copies/mL it will be repeated within 2 weeks. If after adherence counseling, HIV RNA demonstrates > 1 log 10 decline but remains >500, the patient will receive a final adherence counseling session and have his/her HIV RNA measure repeated at day 30: if a third consecutive HIV RNA remains 500 c/mL the patient will be removed from study, if <500c/mL the patient will remain on study
Week 48
Tolerability and Adverse Events.
Tidsramme: 48 weeks
Adverse events and safety parameters are monitored for ll subjects for the duration of the study. Toxicities and adverse events will be graded using the modified ACTG toxicity ratings scale. Study drugs may be interrupted for safety reasons and/or based on grade of toxicity/adverse event.
48 weeks
Change From Baseline Fasting Total Cholesterol and Fasting Triglyceride Levels.
Tidsramme: 48 weeks
Change from baseline fasting total cholesterol and fasting triglyceride levels will be measured by fasting lipid panels taken at baseline and at various timepoints.
48 weeks
Characterize Adherence Rates for This Therapeutic Regimen by the Use of Medication Electronic Monitoring Systems (MEMS) Caps.
Tidsramme: 48 weeks
The medication event monitoring system (MEMS) is a cap that fits on standard medicine bottles and records the time and date each time the bottle is opened and closed.
48 weeks
Characterize Adherence Rates for This Therapeutic Regimen by Use of Pharmacy Refill Records.
Tidsramme: 48 weeks
Characterize adherence rates for this therapeutic regimen by use of pharmacy refill records is assessed by an examination of pharmacy refill data for patients.
48 weeks
Assess Genotypic Changes in Patients With Virologic Failure.
Tidsramme: 48 weeks
At time of virologic failure genotypes will be performed on baseline and failure isolates; phenotypic testing will be performed on failure isolates to examine LPV susceptibility.
48 weeks
Assess Lopinavir Trough Levels in Patients Failing to Obtain Virologic Suppression.
Tidsramme: 48 weeks
Assess lopinavir trough levels in patients failing to obtain virologic suppression by measuring lopinavir trough level
48 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Oklahoma State University Center for Health Sciences

Samarbejdspartnere

Abbott

Efterforskere

  • Ledende efterforsker: Damon Baker, D.O., Oklahoma State University Center for Health Sciences

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2008

Primær færdiggørelse (Faktiske)

1. maj 2011

Studieafslutning (Faktiske)

1. maj 2011

Datoer for studieregistrering

Først indsendt

15. maj 2008

Først indsendt, der opfyldte QC-kriterier

16. maj 2008

Først opslået (Skøn)

19. maj 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. december 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. december 2020

Sidst verificeret

1. december 2020

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • Baker - 001

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med HIV-infektioner

Kliniske forsøg med Once daily

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Burundi

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner